摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-4-羟基去甲基麻黄素; (1R,2S)-2-氨基-1-(4-羟基苯基)丙-1-醇 | 771-91-5

中文名称
(-)-4-羟基去甲基麻黄素; (1R,2S)-2-氨基-1-(4-羟基苯基)丙-1-醇
中文别名
(-)-4-羟基去甲基麻黄素;(-)-4-羟基去甲基麻黄素;(1R,2S)-2-氨基-1-(4-羟基苯基)丙-1-醇;(1R,2S)-2-氨基-1-(4-羟基苯基)丙-1-醇
英文名称
(-)-4-Hydroxynorephedrin
英文别名
4-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
(-)-4-羟基去甲基麻黄素; (1R,2S)-2-氨基-1-(4-羟基苯基)丙-1-醇化学式
CAS
771-91-5
化学式
C9H13NO2
mdl
——
分子量
167.2
InChiKey
JAYBQRKXEFDRER-RCOVLWMOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    66.5
  • 氢给体数:
    3
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE
    申请人:Sumitomo Pharmaceuticals Company, Limited
    公开号:EP1514869A1
    公开(公告)日:2005-03-16
    The compound of the formula (I): wherein W is a group of the following formula (VIII) binding to any possible position on the Q: Q is, together with W, a group of the formula: -C(M=C(R3A)-N(R3)-, etc.; R3A is H or optionally substituted lower alkyl; R4, R5, R6, and R7 are independently H or optionally substituted lower alkyl; R1 is optionally substituted lower alkyl, etc.; R2 is H, etc.; R3 is H, etc.; Ar is phenyl, etc., or a pharmaceutically acceptable salt thereof, where these compounds exhibiting β3-adrenoceptor-stimulating activity and being useful as a medicament for treatment of obesity, etc.
    公式(I)的化合物: 其中W是以下公式(VIII)的基团,可以与Q的任何可能位置结合: Q与W一起是以下公式的基团:-C(M=C(R3A)-N(R3)-等; R3A是H或可选地取代的低级烷基;R4、R5、R6和R7独立的是H或可选地取代的低级烷基;R1是可选地取代的低级烷基等;R2是H等;R3是H等;Ar是苯基等,或其药物可接受的盐,其中这些化合物具有β3-肾上腺素受体刺激活性,并作为治疗肥胖等的药物有用。
  • Aminoalcohol derivatives
    申请人:Hattori Kouji
    公开号:US20050137236A1
    公开(公告)日:2005-06-23
    The present invention relates to a compound formula[I]: wherein X is bond, —CH 2 —, —O— or —NH—, R 1 and R 12 are each independently hydrogen, halogen, lower alkyl, etc., R 2 is hydrogen or optionally substituted lower alkyl, R 3 is hydrogen or an amino protective group, R 4 , R 5 and R 6 are each independently hydrogen or optionally substituted lower alkyl, R 7 is -Z-R 13 , in which Z is bond, etc., and R 13 is carboxy, lower alkoxycarbonyl, (lower alkylsulfonyl)carbamoyl or lower alkanoylsulfamoyl, R 8 is —Y—R 9 , in which Y is bond, —CH 2 —, —O—, —S—, etc., and R 9 is hydrogen, lower alkyl, cyclo(lower)alkyl, etc., and R 11 is hydrogen, lower alkyl, lower alkoxy, etc., or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
    本发明涉及一种化合物公式[I]: 其中 X是键,—CH 2 —,—O—或—NH—, R 1 和R 12 分别独立地是氢,卤素,较低的烷基等, R 2 是氢或可选择地取代的较低烷基, R 3 是氢或基保护基, R 4 ,R 5 和R 6 分别独立地是氢或可选择地取代的较低烷基, R 7 是-Z-R 13 ,在其中Z是键等,而 R 13 是羧基,较低的烷氧羰基,(较低的烷基磺酰)基甲酰或较低的烷酰磺酰基, R 8 是—Y—R 9 ,在其中 Y是键,—CH 2 —,—O—,—S—等,而 R 9 是氢,较低的烷基,环(较低)烷基等,而 R 11 是氢,较低的烷基,较低的烷氧基等,或其盐。本发明的化合物[I]及其药学上可接受的盐对于预防和/或治疗尿频或尿失禁具有用处。
  • Synthesis of phenoxyacetic acid derivatives
    申请人:Winter Eric
    公开号:US20070088174A1
    公开(公告)日:2007-04-19
    The present invention relates to an improved process for the preparation of substituted 2-(4-carbonylmethoxy-optionally 2,5-disubstituted-phenyl)-acetaldehydes, in particular 2-(4-alkoxycarbonylmethoxy-optionally 2,5-disubstituted-phenyl)-acetaldehydes and their use in the synthesis of optionally substituted 2-[4-[2-[[-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-amino]ethyl]-optionally 2,5-disubstituted-phenoxy]acetic acid derivatives or the salts thereof, which may be used as pharmaceutically active substances.
    本发明涉及一种改进的方法,用于制备取代的2-(4-羰基甲氧基-可选地2,5-二取代苯基)-乙醛,特别是2-(4-烷氧羰基甲氧基-可选地2,5-二取代苯基)-乙醛及其在合成可选地取代的2-[4-[2-[[-2-羟基-2-(4-羟基苯基)-1-甲基乙基]-基]乙基]-可选地2,5-二取代苯氧基]乙酸生物或其盐中的用途,这些衍生物可用作药用活性物质。
  • 2-methylpropionic acid derivatives and pharmaceutical compositions comprising the same
    申请人:KISSEI PHARMACEUTICAL CO., LTD.
    公开号:US20030166719A1
    公开(公告)日:2003-09-04
    The present invention provides novel 2-methylpropionic acid derivatives represented by the general formula: 1 (wherein R 1 represents a hydroxy group, a lower alkoxy group or an aralkyl group; R 2 represents a hydroxy group, a lower alkyl group or a halogen atom; A represents an oxygen atom or an imino group; the carbon atom marked with (R) represents a carbon atom in R configuration; and the carbon atom marked with (S) represents a carbon atom in S configuration) and pharmaceutically acceptable salts thereof, which have excellent &bgr; 3 -adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract.
    本发明提供了一种新的2-甲基丙酸生物,其通式表示为:1(其中R1代表一个羟基、一个较低的烷氧基或一个芳基烷基;R2代表一个羟基、一个较低的烷基或一个卤原子;A代表一个氧原子或一个亚胺基;标有(R)的碳原子代表R构型中的一个碳原子;标有(S)的碳原子代表S构型中的一个碳原子),以及其药学上可接受的盐,具有优异的β3-肾上腺素受体刺激效应,可用作预防或治疗肥胖、高血糖、由肠道过度运动引起的疾病、尿频、尿失禁、抑郁症或胆结石或胆道过度运动引起的疾病的药剂。
  • [EN] PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] DERIVES D'ACIDE PHENOXYACETIQUE ET COMPOSITIONS MEDICINALES CONTENANT LESDITS DERIVES
    申请人:KISSEI PHARMACEUTICAL
    公开号:WO2000002846A1
    公开(公告)日:2000-01-20
    Novel phenoxyacetic acid derivatives represented by general formula (I), and pharmacologically acceptable salts thereof, which exhibit an excellent β3-adrenergic receptor stimulating effect and are useful as preventive or therapeutic agents for obesity, hyperglycemia, diseases due to hyperkinesia of intestine, pollakiuria, urinary incontinence, depression, cholelithiasis or diseases due to hyperkinesia of biliary tract: wherein R1 is hydroxyl or the like; one of R?2 and R3¿ is hydrogen, halogeno or the like, and the other thereof is hydrogen; and R4 is halogeno or the like.
    化合物的一般公式(I)及其药理学上可接受的盐,具有优异的β3-肾上腺素能受体刺激效应,并可作为预防或治疗肥胖症、高血糖症、肠道过动症、尿频、尿失禁、抑郁症、胆石症或胆道过动症的治疗剂使用:其中R1为羟基或类似物;R?2和R3¿中的一个是氢、卤素或类似物,另一个是氢;R4为卤素或类似物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫